# ActiTrexx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/actitrexx

- Industry: Biotechnology
- Headquarters: Mainz, Germany
- Website: www.actitrexx.de
- Total disclosed funding: $4.3M
- Latest round: Series A (Jan 19, 2021)
- Investors on record: 4

## About

Founded in 2019 and based in Mainz, Germany, ActiTrexx GmbHv operates as a provider of preventive medicine for graft versus disease or (GvHD). The company was co-founded by Prof. Andrea Tüttenberg and Dr. Helmut Jonuleit. In March 2021, ActiTrexx GmbH received EUR 3.5 million in Series A funding from BBW Venture Capital GmbH, MediVentures GmbH, High-Tech Gründerfonds (HTGF), and Investitions- und Strukturbank Rheinland-Pfalz (ISB).

The company offers cell therapy treatment for patients who undergoes cell transplants to avoid graft versus host disease. The company product called "ATreg"  a cell therapy made from regulatory T cells that are stimulated using a proprietary method intended to help patients with possible fatal rejection enables them to prevent body rejection reactions.

As of March 2021, the company plans to optimize and clinically test the new cell therapy.

## Funding rounds

- Series A, Jan 19, 2021, $4.3M — LBBW Venture Capital, High-Tech Gruenderfonds, Investitions- und Strukturbank Rheinland-Pfalz, MediVentures

## Investors

- LBBW Venture Capital (https://capitalatlas.ai/funds/lbbw-venture-capital) — Series A
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Series A
- Investitions- und Strukturbank Rheinland-Pfalz (https://capitalatlas.ai/funds/investitions-und-strukturbank-rheinland-pfalz) — Series A
- MediVentures — Series A